NCT00701415 A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Status COMPLETED Phase PHASE3
NCT00526071 Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Status TERMINATED Phase PHASE2
NCT00487630 Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease Status UNKNOWN Phase PHASE4
NCT00446862 The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study Status COMPLETED Phase N/A
NCT00413595 Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation Status COMPLETED Phase N/A
NCT00357786 An Open-Label Maintenance Study of the Enzyme Replacement Therapy Replagal in Patients With Fabry Disease Status COMPLETED Phase PHASE1
NCT00312767 A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency. Status WITHDRAWN Phase PHASE4
NCT00304512 A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Status COMPLETED Phase PHASE2
NCT00283959 A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Status COMPLETED Phase PHASE2
NCT00283933 A 24-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Status COMPLETED Phase PHASE2
NCT00233870 A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease. Status COMPLETED Phase N/A
NCT00230607 Study of the Effects of Fabrazyme Treatment on Lactation and Infants Status TERMINATED Phase PHASE4
NCT00214500 A Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Status COMPLETED Phase PHASE2
NCT00196716 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Status COMPLETED Phase PHASE2
NCT00140621 A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease Status COMPLETED Phase PHASE4